Audrey Lupo
Paris Descartes University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Audrey Lupo.
Clinical Cancer Research | 2015
Nicolas A. Giraldo; Etienne Becht; Franck Pagès; Georgios P Skliris; Virginie Verkarre; Yann Vano; Arnaud Mejean; Nicolas Saint-Aubert; Laetitia Lacroix; Ivo Natario; Audrey Lupo; Marco Alifano; Diane Damotte; Aurélie Cazes; Frédéric Triebel; Gordon J. Freeman; Marie-Caroline Dieu-Nosjean; S. Oudard; Wolf-Herman Fridman
Purpose: Clear cell renal cell carcinoma (ccRCC) has shown durable responses to checkpoint blockade therapies. However, important gaps persist in the understanding of its immune microenvironment. This study aims to investigate the expression and prognostic significance of immune checkpoints in primary and metastatic ccRCC, in relation with mature dendritic cells (DC) and T-cell densities. Experimental Design: We investigated the infiltration and the localization of CD8+ T cells and mature DC, and the expression of immune checkpoints (PD-1, LAG-3, PD-L1, and PD-L2) in relation with prognosis, in 135 primary ccRCC tumors and 51 ccRCC lung metastases. RNA expression data for 496 primary ccRCC samples were used as confirmatory cohort. Results: We identify two groups of tumors with extensive CD8+ T-cell infiltrates. One group, characterized by high expression of immune checkpoints in the absence of fully functional mature DC, is associated with increased risk of disease progression. The second group, characterized by low expression of immune checkpoints and localization of mature DC in peritumoral immune aggregates (tertiary lymphoid structures), is associated with good prognosis. Conclusions: The expression of the immune checkpoints and the localization of DC in the tumor microenvironment modulate the clinical impact of CD8+ T cells in ccRCC. Clin Cancer Res; 21(13); 3031–40. ©2015 AACR.
Cancer Research | 2016
Jitka Fucikova; Etienne Becht; Kristina Iribarren; Jeremy Goc; Romain Remark; Diane Damotte; Marco Alifano; Priyanka Devi; Jérôme Biton; Claire Germain; Audrey Lupo; Wolf Hervé Fridman; Marie-Caroline Dieu-Nosjean; Guido Kroemer; Isabelle Cremer
A high density of tumor-infiltrating mature dendritic cells (DC) and CD8(+) T cells correlates with a positive prognosis in a majority of human cancers. The recruitment of activated lymphocytes to the tumor microenvironment, primed to recognize tumor-associated antigens, can occur in response to immunogenic cell death (ICD) of tumor cells. ICD is characterized by the preapoptotic translocation of calreticulin (CRT) from the endoplasmic reticulum (ER) to the cell surface as a result of an ER stress response accompanied by the phosphorylation of eukaryotic initiation factor 2α (eIF2α). We conducted a retrospective study on two independent cohorts of patients with non-small cell lung cancer (NSCLC) to investigate the prognostic potential of CRT. We report that the level of CRT expression on tumor cells, which correlated with eIF2α phosphorylation, positively influenced the clinical outcome of NSCLC. High CRT expression on tumor cells was associated with a higher density of infiltrating mature DC and effector memory T-cell subsets, suggesting that CRT triggers the activation of adaptive immune responses in the tumor microenvironment. Accordingly, patients with elevated CRT expression and dense intratumoral infiltration by DC or CD8(+) T lymphocytes had the best prognosis. We conclude that CRT expression constitutes a new powerful prognostic biomarker that reflects enhanced local antitumor immune responses in the lung. Cancer Res; 76(7); 1746-56. ©2016 AACR.
Radiology | 2018
Marie-Pierre Revel; Inès Mannes; Joseph Benzakoun; Claude Guinet; Thomas Léger; Philippe Grenier; Audrey Lupo; Ludovic Fournel; Guillaume Chassagnon; Sébastien Bommart
Purpose To evaluate an objective computed tomographic (CT) criterion for distinguishing between part-solid (PS) and nonsolid (NS) lung nodules. Materials and Methods This study received institutional review board approval, and patients gave informed consent. Preoperative CT studies in all patients who underwent surgery for subsolid nodules between 2008 and 2015 were first reviewed by two senior radiologists, who subjectively classified the nodules as PS or NS. A second reading performed 1 month later used predefined classification criteria and involved a third senior radiologist as well as three junior radiologists. Subsolid nodules were classified as PS if a solid portion was detectable in the mediastinal window setting (nonmeasurable, < 50%, or > 50% of the entire nodule) and were otherwise classified as NS (subclassified as pure or heterogeneous). Interreader agreement was assessed with κ statistics and the intraclass correlation coefficient (ICC). Results A total of 99 nodules measuring a median of 20 mm (range, 5-47 mm) in lung window CT images were analyzed. Senior radiologist agreement on the PS/NS distinction increased from moderate (κ = 0.54; 95% confidence interval [CI]: 0.37, 0.71) to excellent (κ = 0.89; 95% CI: 0.80, 0.98) between the first and second readings. At the second readings, agreement among senior and junior radiologists was excellent for PS/NS distinction (ICC = 0.87; 95% CI: 0.83, 0.90) and for subcategorization (ICC = 0.82; 95% CI: 0.77, 0.87). When a solid portion was measurable in the mediastinal window, the specificity for adenocarcinoma invasiveness ranged from 86% to 96%. Conclusion Detection of a solid portion in the mediastinal window setting allows subsolid nodules to be classified as PS with excellent interreader agreement. If the solid portion is measurable, the specificity for adenocarcinoma invasiveness is high.
European Journal of Cardio-Thoracic Surgery | 2016
Ludovic Fournel; Harry Etienne; Audrey Lupo; Diane Damotte; Alexandra Rouquette; Marie-Pierre Revel; Claude Guinet; Marco Alifano; Jean-François Regnard
Abstract The aim of this study was to evaluate, in a predominantly white population, correlations between radiological and pathological diagnoses based on the latest classifications of pulmonary adenocarcinomas. We analysed data from patients undergoing lung resection for ground glass nodules (GGNs) less than 3 cm and whose solid component was
OncoImmunology | 2016
Romain Remark; Audrey Lupo; Marco Alifano; Jerome Biton; Hanane Ouakrim; Alessandro Stefani; Isabelle Cremer; Jérémy Goc; Jean-François Regnard; Marie-Caroline Dieu-Nosjean; Diane Damotte
ABSTRACT There is now growing evidence that the immune contexture influences cancer progression and clinical outcome of patients with non-small cell lung cancer (NSCLC). If chemotherapy is widely used to treat patients with advanced-stage NSCLC, it remains unclear how it could modify the immune contexture and impact its prognostic value. Here, we analyzed two retrospective cohorts, respectively composed of 122 stage III-N2 NSCLC patients treated with chemotherapy before surgery and 39 stage-matched patients treated by surgery only. In patients treated with neoadjuvant chemotherapy, the histological characteristics, the expression of PD-L1 protein, and the tumor immune microenvironment (CD8+ T cells, DC-LAMP+ mature dendritic cells, and CD68+ macrophages) were evaluated and their prognostic value assessed together with standard clinical parameters. By analyzing pre- and post-treatment specimens, we did not find any changes in the PD-L1 expression. We also found that the tumor immune contexture in patients treated with neoadjuvant chemotherapy exhibited a similar pattern that the one found in chemotherapy-naive patients, with comparable densities of tumor-infiltrating CD8+ and DC-LAMP+ cells and a similar spatial organization. The percentage of residual viable tumor cells and the immune pattern (CD8+ and DC-LAMP+ cell densities) were significantly associated with the clinical outcome and allowed the identification of short- and long-term survivors, respectively. In multivariate analysis, the immune pattern was found to be the strongest independent prognostic factor. In conclusion, this study decrypts the complex interplay between cancer and immune cells in patients undergoing chemotherapy and supports potential beneficial synergistic effect of immunotherapy and chemotherapy.
Clinical Cancer Research | 2013
Romain Remark; Marco Alifano; Isabelle Cremer; Audrey Lupo; Marie-Caroline Dieu-Nosjean; Marc Riquet; Lucile Crozet; Hanane Ouakrim; Jeremy Goc; Aurélie Cazes; Jean-François Fléjou; Laure Gibault; Virginie Verkarre; Jean-François Regnard; Olivier-Nicolas Pagès; Stéphane Oudard; Bernhard Mlecnik; Wolf-Herman Fridman; Diane Damotte
Oncotarget | 2014
Mohamad Younes; Zherui Wu; Sandra Dupouy; Audrey Lupo; Najat Mourra; Takashi Takahashi; Jean François Fléjou; Jean Trédaniel; Jean François Regnard; Diane Damotte; Marco Alifano; Patricia Forgez
The Annals of Thoracic Surgery | 2013
Salvatore Strano; Audrey Lupo; F. Lococo; Olivier Schussler; Mauro Loi; Mohamad Younes; Antonio Bobbio; Diane Damotte; Jean Francois Regnard; Marco Alifano
Lung | 2015
Aurélie Janet-Vendroux; Mauro Loi; Antonio Bobbio; Filippo Lococo; Audrey Lupo; Pauline Ledinot; Pierre Magdeleinat; Nicolas Roche; Diane Damotte; Jean François Regnard; Marco Alifano
European Respiratory Journal | 2014
Antonio Bobbio; Marco Alifano; Audrey Lupo; Nicolas Roche; Jean-François Regnard; Isabelle Cremer; Marie-Caroline Dieu-Nosjean; Diane Damotte